| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8630331 | Diabetes Research and Clinical Practice | 2018 | 29 Pages |
Abstract
Given the very small prevalence of bladder cancer in diabetic patients exposed (or not) to pioglitazone (<0.3%) and the much greater beneficial effects of the drug on CVD and NASH, the use of pioglitazone should be resurrected.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Mayer B. Davidson, Deyu Pan,